Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 79

Oral tranexamic acid after total shoulder replacement to reduce bleeding and help early recovery.

Official title: Evaluating the Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty: A Randomized Control Trial

Run by University of Alabama at Birmingham · NCT06902714 · Data updated 2026-11-12

This Phase 3 study will test whether taking oral tranexamic acid after a total shoulder replacement helps adults 18–79 have less bleeding and better short-term recovery compared with a placebo.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 79 Years
SexAll
Enrollment60 (estimated)
SponsorUniversity of Alabama at Birmingham
Academic / other
Locations1 site (Birmingham, Alabama)
StatusRecruiting
StartedApril 20, 2026
Main results expectedJuly 2028
Study endsDecember 2030
Registry record updatedApril 28, 2026
Trial IDNCT06902714 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–79 having a primary total shoulder replacement who do not have active cancer, recent clotting or stroke history, significant heart disease, pregnancy or breastfeeding, allergy to TXA, current tobacco use, or use of anticoagulants other than aspirin are appropriate candidates.

Probably not a fit

Patients with a history of venous thromboembolism, recent stroke, significant cardiac disease, active cancer, pregnancy or nursing, TXA allergy, current tobacco use, or who take anticoagulants other than aspirin are excluded and unlikely to receive benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional study at the University of Alabama at Birmingham gives patients undergoing primary total shoulder arthroplasty an extended postoperative course of either oral tranexamic acid or a matching placebo. Participants are skeletally mature adults aged 18–79 and those with active cancer, prior venous thromboembolism or stroke, significant heart disease, pregnancy or nursing, TXA allergy, current tobacco use, or use of anticoagulants other than aspirin are excluded. The trial focuses on short-term postoperative clinical outcomes, including measures related to bleeding, hemoglobin, wound complications, and early functional recovery. Results will show whether an extended oral TXA regimen improves early recovery after shoulder replacement compared with placebo.

Why it matters

Potential benefit: If successful, taking oral tranexamic acid after shoulder replacement could reduce postoperative bleeding and speed early recovery.

How similar studies have gone: Previous work in hip and knee arthroplasty and some shoulder procedures has shown that tranexamic acid can reduce blood loss and transfusion needs, but extended postoperative oral regimens after shoulder replacement are less well studied.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Skeletally mature patients (ages 18-79) undergoing primary total shoulder arthroplasty

Exclusion Criteria:

* Patients with Cancer, venous thromboembolism, stroke, heart disease, pregnant or nursing, allergic to TXA, current tobacco use, anticoagulants other than aspirin.

Where it's running

  • University of Alabama at Birmingham
    Birmingham, Alabama, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.